The last time I spoke about Upstream Bio, Inc. (UPB), it was in a Seeking Alpha article entitled "Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study." With respect to ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The stock ...
– Data support the potential of verekitug’s unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – “We continue to ...
Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results